2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Blood Banking, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Non-Biological Therapies, Opioids, Workforce, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Hemoglobinopathies, Sickle Cell Disease, Metabolic Disorders, Iron Overload, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4366 Low confidence in sickle cell disease management and unequal access to sickle cell care expertise among clinicians in federally qualified health centers

Samuel Keyes, Philippa Sprinz, MD, MSc2, Vinal Menon, PhD3, Sophie Lanzkron, MD, MHS4
1 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
2 Brown University, Warren Alpert Medical School, Providence, Rhode Island, United States
3 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
4 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Background: Sickle cell disease (SCD) affects over 100,000 people in the US. Federally Qualified Health Centers (FQHCs) are community-based safety-net clinics that deliver comprehensive primary care, dental, and mental health services to underserved populations. One author (PS) is a member of MAVEN Project, a national telehealth non-profit that connects expert physician volunteers with primary care providers (PCPs) at FQHCs. PS provides virtual consultation with clinicians caring for people with SCD. The number of people with SCD who receive primary care through FQHCs is unknown. Research has shown that many PCPs do not feel confident managing SCD. The limited availability of knowledgeable clinicians, including hematologists skilled in SCD treatment, is well recognized. This HRSA-funded study used a survey-based methodology to examine FQHC provider confidence in the treatment of SCD and the availability of referral resources within their practice settings.

Methods: Data was collected using a REDCap survey electronically distributed to FQHC providers (MDs, DOs, NPs, and PAs) through MAVEN Project. The survey collected information on providers’ demographic characteristics, training, practice setting, and the availability of hematologists for patient referral. Comfort with SCD treatment and pain management was assessed on a five-item Likert scale (strongly agree to strongly disagree). Responses were retained only for providers who reported treating at least one SCD patient in an average month. Logistic regression was used to assess the association between provider type (physician vs NP/PA) and comfort managing pain, prescribing hydroxyurea, or prescribing opioids, controlling for the average number of SCD patients cared for each month. All analyses were performed using R version 4.5.3.

Results: 198 complete unique survey responses were received from across the US (12% Midwest, 50% Northeast, 10% South, 28% West). 57 (29%) providers cared for adults only, 106 (54%) cared for both adults and children, and 35 (18%) cared for children only. 181 providers (91%) cared for between one and <10 people with SCD in the past month, while 17 (9%) cared for ≥10 SCD patients. 92 (46%) providers felt confident caring for people with SCD. 86 providers (43.4%) agreed or strongly agreed that they were comfortable managing pain in people with SCD, 87 providers (44%) agreed or strongly agreed that they were comfortable prescribing opioids, and 40 providers (20%) agreed or strongly agreed that they were comfortable prescribing and monitoring hydroxyurea. After adjusting for the average number of SCD patients cared for each month, physicians were significantly more likely than NPs/PAs to be comfortable managing pain (adjusted OR 2.84, 95% CI 1.57-5.21, p < 0.001), prescribing opioids (adjusted OR 2.17, 95% CI 1.20-3.94, p = 0.01), and prescribing and monitoring hydroxyurea (adjusted OR 2.42, 95% CI 1.17-5.06, p = 0.017). The number of SCD patients cared for in the average month was not independently associated with comfort managing pain or prescribing opioids but was associated with comfort prescribing hydroxyurea (adjusted OR 1.80, 95% CI 1.03-3.09, p = 0.031). Among surveyed physicians, 49 (65%) had their last didactic on SCD care in residency or earlier. Of the 106 (54%) providers who did not feel comfortable providing care for individuals with SCD, 26% did not have access to a sickle cell expert as a resource. 164 (83%) of providers had access to a SCD expert or hematologist for patient referral, and 93% of the providers who had referral access chose to refer all patients with SCD.

Discussion: Despite efforts to increase the sickle cell clinician workforce, gaps in access to high-quality care remain. Many providers who report confidence treating people with SCD remain uncomfortable with key elements of the standard of care. Clinicians in FQHCs are more comfortable writing opioids than managing disease modifying therapy, reinforcing the need for referral to a sickle cell expert. Connecting sickle cell experts with clinicians in their communities, in person and through telemedicine, may help overcome these gaps. In addition, hub and spoke models embedded in safety net clinics may allow for improved access to high quality care.
Samuel Keyes: No relevant conflicts of interest to declare.